Evidence map›Paper›PMID 35342422›Full record

ArticleJournal of oncology2022

Analysis of Serum IgG1 to Predict Progression and Therapeutic Effect in Patients with Multiple Myeloma.

Jingping Yin, Jun Qiu, Zheng Zhang, Bin Feng, Jinfang Shi, Dong Zheng

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jingping YinCenter of Clinical Laboratory, The First Affiliated Hospital of Soochow University, Suzhou 215008, Jiangsu, China.
Jun QiuCenter of Clinical Laboratory, The First Affiliated Hospital of Soochow University, Suzhou 215008, Jiangsu, China.
Zheng ZhangCenter of Clinical Laboratory, The First Affiliated Hospital of Soochow University, Suzhou 215008, Jiangsu, China.
Bin FengCenter of Clinical Laboratory, The First Affiliated Hospital of Soochow University, Suzhou 215008, Jiangsu, China.
Jinfang ShiCenter of Clinical Laboratory, The First Affiliated Hospital of Soochow University, Suzhou 215008, Jiangsu, China.
Dong ZhengCenter of Clinical Laboratory, The First Affiliated Hospital of Soochow University, Suzhou 215008, Jiangsu, China.ORCID https://orcid.org/0000-0002-6299-9994
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The correlation between laboratory indicators and clinical treatment effects and the prognosis of multiple myeloma remains poorly understood. Therefore, our study investigated whether serum IgG subclasses could be employed as potential indicators contributed to evaluate the therapeutic effect and prognosis of patients with multiple myeloma. Results: In 560 study patients with multiple myeloma, serum IgA, IgG, IgM, Conclusion: Serum IgG1 level could serve as the potential indicator for evaluating the therapeutic effect for patients with multiple myeloma.

Identifiers

PMID35342422
PMCPMC8947869
OpenAlexW4220757857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.